An interventional study of Intensity-modulated proton therapy (IMPT) and Photon-based intensity-modulated radiation therapy (IMRT). in Brain Tumor, Pediatric, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Tata Memorial Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Brain Neoplasms with a site in India — 9 open to participants now, 10 under way, 3 of them phase 3. Brain Neoplasms · India.
Among the 24 studies in Brain Neoplasms with a site in India, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2025, is one of 2 with no phase, and was the 19th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →9 of the 24 studies in Brain Neoplasms with a site in India are open now. Recruiting first, the newest first:
Tata Memorial Centre · Sites in India
Ages 5+
Tata Memorial Centre · Sites in India
Ages 18–70
Tata Memorial Centre · Sites in India
Ages 5–39
Tata Memorial Centre · Sites in India
Tata Memorial Centre · Sites in India
Ages 18+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 6 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 94 is above the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 156 across the 11 interventional studies, 1,372 across the 13 observational. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 24 have an industry lead sponsor. The 10 most frequent:
Tata Memorial Centre is the lead sponsor of 64 studies on the registry; 42 are open to participants now.
Tata Memorial Centre has 7 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Brain Neoplasms with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06381531Tata Memorial CentreTracing Brain Tumors Through Deep Time | 2027-06-10 |
| NCT07236840Tata Memorial CentreSelf-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Brain Neoplasms with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Children diagnosed with benign or low-grade brain tumors often require radiation therapy to control their disease. While radiation can be effective, traditional techniques using X-rays (photon-based radiotherapy) expose healthy brain tissue to radiation, potentially leading to long-term side effects like memory loss, learning difficulties, hormone imbalances, hearing problems, and a higher risk of secondary cancers. This study, called the IMPORT Trial, aims to compare two types of radiation therapy-Intensity-Modulated Proton Therapy (IMPT) and Intensity-Modulated Radiation Therapy (IMRT)-to determine which is safer and more effective for children. IMPT, a newer technique, uses protons instead of X-rays to deliver radiation, reducing exposure to healthy brain tissue. Researchers believe this could help minimize long-term damage while maintaining effective tumor control.
What is the goal of the study?
The primary goal is to see if IMPT leads to better survival with fewer side effects compared to IMRT. The study will track how well children function over five years, looking at:
How will the study work?
Proton therapy is more expensive and not widely available, so strong scientific evidence is needed to justify its use in routine treatment. If IMPT significantly improves quality of life and survival, it could become the preferred treatment, shaping future policies and making proton therapy more accessible for children who need it.
Benign and low-grade primary brain tumors constitute a substantial proportion of pediatric central nervous system tumors and are associated with excellent long-term survival when managed with multimodality therapy. Despite favorable tumor control rates, survivors are at significant risk of treatment-related late effects, particularly following radiation therapy, which can adversely impact neurocognitive function, endocrine health, auditory function, and overall quality of life. Given the prolonged life expectancy of this population, minimizing radiation-induced toxicity while maintaining effective disease control is a major therapeutic priority.
Radiation therapy remains an essential curative modality for children with unresectable, residual, progressive, or recurrent benign and low-grade brain tumors. Advances in high-precision photon-based techniques such as intensity-modulated radiation therapy (IMRT) have improved dose conformality; however, photon therapy continues to expose large volumes of normal brain tissue to low and intermediate radiation doses. This exposure may lead to white matter injury, neuroinflammation, microvascular damage, and subsequent neurocognitive, endocrine, and auditory dysfunction, particularly in younger patients with developing brains.
Proton beam therapy offers a potential dosimetric advantage over photon therapy due to its physical depth-dose characteristics, allowing reduced integral dose to surrounding normal tissues. Intensity-modulated proton therapy (IMPT), delivered using pencil beam scanning, enables highly conformal dose distributions with improved sparing of organs at risk and may allow for reduction in treatment margins through enhanced image guidance and dose painting capabilities. These properties suggest a potential for meaningful reduction in late radiation-related toxicity in pediatric patients, while preserving tumor control.
While dosimetric and retrospective clinical data suggest advantages of proton therapy in reducing radiation exposure to critical neural structures, robust prospective randomized evidence demonstrating clinically meaningful benefits remains limited. Furthermore, the higher cost and limited availability of proton therapy necessitate careful evaluation of its value relative to advanced photon techniques, particularly in resource-constrained healthcare systems. Generating high-level evidence to guide patient selection and policy decisions is therefore essential.
The IMPORT trial is a prospective, randomized, open-label, phase III superiority study designed to compare IMPT with IMRT in children with benign and low-grade primary brain tumors treated with curative intent radiotherapy. The trial focuses on outcomes that are particularly relevant to long-term pediatric survivorship, including neurocognitive function, endocrine and auditory toxicity, and quality of life, while ensuring comparable tumor control.
The study introduces the concept of Qualified Overall Survival (qOS) as a composite primary endpoint that integrates survival, disease control, and clinically significant treatment-related morbidity. This composite endpoint is intended to capture outcomes that reflect both oncologic efficacy and functional preservation, thereby providing a patient-centered assessment of treatment benefit.
Participants will be randomized to receive either IMPT or IMRT, with radiation dose, fractionation, and target volumes determined by tumor type, location, and standard clinical practice. Tumor response and disease progression will be assessed using contemporary imaging-based criteria, while functional outcomes will be evaluated using standardized neurocognitive testing, endocrine assessments, audiological evaluations, and patient-reported quality-of-life instruments.
By directly comparing IMPT and IMRT in a randomized setting, the IMPORT trial aims to determine whether the dosimetric advantages of proton therapy translate into superior long-term functional outcomes and improved qualified survival, thereby informing evidence-based clinical decision-making and health policy for pediatric brain tumor management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the standard arm will undergo focal cranial radiotherapy using photons (X-rays) with Image Guided Intensity Modulated Radiotherapy(IG-IMRT) using Volumetric Modulated Arc Therapy(VMAT).
Radiation: Photon-based intensity-modulated radiation therapy (IMRT).
The patients in the experimental arm will undergo focal radiotherapy to an equivalent dose using protons with pencil beam scanning- IMPT or volumetric modulated proton arc therapy.
Radiation: Intensity-modulated proton therapy (IMPT)
Patients in the experimental arm will receive focal cranial radiotherapy using proton therapy delivered with IMPT or proton arc techniques. Dose prescriptions and volumes will match institutional standards independent of study allocation. Planning will include CT and MRI fusion, with target and OAR delineation identical to the control arm. Proton plans will use robust optimization and undergo multidisciplinary review. Treatment will be delivered with image guidance, with weekly toxicity monitoring and standard clinical and imaging follow-up.
Patients in the control arm will receive focal cranial radiotherapy using photon-based IG-IMRT delivered with VMAT. Dose, fractionation, and target volumes will follow standard institutional protocols based on tumor type and molecular features. Planning CT and MRI fusion will guide contouring of GTV, CTV, PTV, and organs at risk. Treatment plans will be generated in the Treatment Planning System and reviewed in multidisciplinary meetings. Radiotherapy will be delivered on IGRT-equipped linear accelerators, with weekly assessments for acute toxicities and routine follow-up imaging as per standard care.
Survival Outcome
Qualified Overall Survival (qOS) is a composite endpoint defined as survival without functional, cognitive, or quality-of-life deterioration, irrespective of whether the cause is disease progression or treatment toxicity. The study hypothesizes that IMPT is superior to IMRT for 5-year qOS. qOS is measured from randomization to the earliest of: 1. death from any cause; 2. radiological progression confirmed on multiparametric MRI with two scans ≥12 weeks apart or deemed progressive by multidisciplinary consensus; 3. neurocognitive decline \>10 IQ points on Wechsler scales; 4. clinically significant hypopituitarism requiring hormonal supplementation (CTCAE v5 Grade ≥2); 5. Grade ≥2 ototoxicity; or 6. symptomatic radiation necrosis requiring corticosteroids \>4 weeks or anti-angiogenic therapy (e.g., bevacizumab).
Time frame: 5 years
Overall Survival (OS)
Overall Survival (defined as the time elapsed between date of randomisation to death due to any cause)
Time frame: At 5 years
Progression-free Survival (PFS)
Progression-free survival(defined as the time elapsed between date of randomisation to documented clinico-radiological progression or death)
Time frame: at 5 years
Quality of Life indices
Quality of life assessed using patient-reported outcome measures developed by the European Organisation for Research and Treatment of Cancer (EORTC), including the core and disease-specific modules administered in this study. Scores are linearly transformed to a range of 0 to 100. For functional scales and global health status, higher scores indicate better quality of life; for symptom scales, higher scores indicate worse symptoms. Assessed at baseline and follow-up. Unit of Measure: Units on a scale
Time frame: Pre-Radiotherapy (Baseline), Radiotherapy conclusion- within 1 week, 3-months post RT, 1-year post RT, annually till 5-years
Cost-effectiveness based on EQ-5D-5L derived utilities
Health-related quality of life for economic evaluation will be assessed using the EuroQol 5-Level 5-Dimension questionnaire (EQ-5D-5L). Responses will be converted to utility scores using a country-specific value set and used to estimate quality-adjusted life years (QALYs) for cost-effectiveness analysis. Assessed at baseline and follow-up. Unit of Measure: Quality-adjusted life years (QALYs)
Time frame: Pre-Radiotherapy (Baseline), Radiotherapy conclusion- within 1 week, 3-months post RT, 1-year post RT, annually till 5-years
Response Rate (RR)
Response Rate (complete and partial response) as decided by contemporary image-based response criteria (RAPNO, RANO-LGG 2.0)
Time frame: Radiotherapy conclusion- within 1 week, 3-months post RT, 1-year post RT, annually till 5-years
Sub-domain of qOS
Cumulative incidence of sub-domains of qualified overall survival
Time frame: Radiotherapy conclusion- within 1 week, 3-months post RT, 1-year post RT, annually till 5-years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jul 2035, 119 months after the start.
Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 119 months is above that.
Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tata Memorial Centre